ArticleACS applied materials & interfaces2020
Evaluating UiO-66 Metal-Organic Framework Nanoparticles as Acid-Sensitive Carriers for Pulmonary Drug Delivery Applications.
Article in ACS applied materials & interfaces, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- COFs on MOFs: Layer-by-Layer Synthesis of MOF@COF Nanoparticles with Synergistic Adsorption.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Metal-Organic Frameworks in Food Biotechnology: Opportunities, Challenges, and Future Perspectives for Probiotic Delivery, Precision Fermentation, and Circular Food Systems.Nanomaterials (Basel, Switzerland) · 2026Review
- Advancements in nanomaterial-based adjuvants for animal vaccines.Materials today. Bio · 2026Article
- Hierarchical Functionalisation of UiO-66(Zr)-NHNanomaterials (Basel, Switzerland) · 2026Article
- UiO-66 metal-organic frameworks in biomedicine: From structural tunability to bioimaging, photodiagnostics, and photodynamic cancer therapy.FEBS open bio · 2026Review
- Toxicity Challenges and Current Advancement in Metal-Organic Frameworks (MOFs) for Biomedical Applications.Biological trace element research · 2026Review
- ZIF-8-Based Nanomedicine for Bone Regeneration: A Critical Appraisal of Preclinical Osteoimmunomodulatory Evidence and Translational Readiness.International journal of nanomedicine · 2026Review
- Biodecolorization and Biodegradation of Methyl Orange by ImmobilizedBiotechnology reports (Amsterdam, Netherlands) · 2025Article
- Insights and advances of theranostic nanoscale metal-organic frameworks.Mikrochimica acta · 2025Review
- Nanomaterials in COPD: Emerging Therapeutic and Diagnostic Frontiers with a Focus on Metal-Organic Frameworks.International journal of molecular sciences · 2025Review
- Nanoparticle-Based Pulmonary Immune Engineering.Annual review of chemical and biomolecular engineering · 2025Review
- Climate friendly MOFs synthesis for drug delivery systems by integrating AI, intelligent manufacturing, and quantum solutions in industry 6.0 sustainable approach.Toxicology research · 2025Review
- Liposome-Based Nanoparticle Delivery Systems for Lung Diseases: Opportunities and Challenges.International journal of nanomedicine · 2025Review
- Virucidal activity of porphyrin-based metal-organic frameworks against highly pathogenic coronaviruses and hepatitis C virus.Materials today. Bio · 2024Article
- Biomedical Metal-Organic Framework Materials: Perspectives and Challenges.Advanced functional materials · 2024Article
- Chitinase-functionalized UiO-66 framework nanoparticles active against multidrug-resistant Candida Auris.BMC microbiology · 2024Article
- Metal-Organic Frameworks: Unconventional Nanoweapons against COVID.ACS applied materials & interfaces · 2024Article
- Preparation of UiO-66 loaded Letrozole nano-drug delivery system: enhanced anticancer and apoptosis activity.AMB Express · 2024Article
- An in-depth physicochemical investigation of drug-loaded core-shell UiO66 nanoMOFs.RSC advances · 2024Article
- KHSRP knockdown inhibits papillary renal cell carcinoma progression and sensitizes to gemcitabine.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Developing novel drug carriers for pulmonary delivery is necessary to achieve higher efficacy and consistency for treating pulmonary diseases while limiting off-target side effects that occur from alternative routes of administration. Metal-organic frameworks (MOFs) have recently emerged as a class of materials with characteristics well-suited for pulmonary drug delivery, with chemical tunability, high surface area, and pore size, which will allow for efficient loading of therapeutic cargo and deep lung penetration. UiO-66, a zirconium and terephthalic acid-based MOF, has displayed notable chemical and physical stability and potential biocompatibility; however, its feasibility for use as a pulmonary drug delivery vehicle has yet to be examined. Here, we evaluate the use of UiO-66 nanoparticles (NPs) as novel pulmonary drug delivery vehicles and assess the role of missing linker defects in their utility for this application. We determined that missing linker defects result in differences in NP aerodynamics but have minimal effects on the loading of model and therapeutic cargo, cargo release, biocompatibility, or biodistribution. This is a critical result, as it indicates the robust consistency of UiO-66, a critical feature for pulmonary drug delivery, which is plagued by inconsistent dosage because of variable properties. Not only that, but UiO-66 NPs also demonstrate pH-dependent stability, with resistance to degradation in extracellular conditions and breakdown in intracellular environments. Furthermore, the carriers exhibit high biocompatibility and low cytotoxicity in vitro and are well-tolerated in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.